Sunday December 8, 2019

Pharma sector calls for drug prices to build in real-world value

The pharmaceutical industry wants future negotiations on drug pricing to include the extent to which drugs prevent costly hospital stays and details of other societal benefits they generate

Susan Mitchell

Deputy Editor and Health Editor

@susmitchellsbp
17th November, 2019
Aidan Lynch: the IPHA president believes price needs to be looked at as an end-to-end cost rather than in isolation Pic: Bryan Meade

The pharmaceutical industry wants future negotiations on drug pricing to include the extent to which drugs prevent costly hospital stays and details of other societal benefits they generate.

Aidan Lynch, general manager of GSK and president of the Irish Pharmaceutical Healthcare Association (IPHA), which represents the industry, said: “If we could look, not just at price in isolation, but at an end-to-end cost, such as bed days and reduced staff required – that type of...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Related Stories

Patient advocates are unhappy with the latest report on the national cervical screening programme and want further reviews, but some medical experts say resources would be better used elsewhere

Susan Mitchell | 18 hours ago

In our rush to condemn CervicalCheck, we’ve overlooked the thousands of women who have survived cervical cancer and the medical and psychological aftercare they need

Donal Brennan | 18 hours ago

The software, purchased from a Chinese company, was acquired at huge cost and may be impossible to use under GDPR law

Rachel Lavin | 18 hours ago